Universität zu Köln

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna Maria, Pflug, Natali, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Preliminary safety results of a placebo-controlled Phase III study of ibrutinib in treatment-nayve early stage CLL patients with risk of disease progression. Leuk. Lymphoma, 56. S. 20 - 22. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Reiser, Marcel, Wendtner, Clemens, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2017). Serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) in early stage patients with CLL treated with ibrutinib or placebo: safety results of the ongoing randomized CLL12 phase III-trial. Leuk. Lymphoma, 58. S. 161 - 163. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Pflug, Natali, Fischer, Kirsten, Stilgenbauer, Stephan, Kreuzer, Karl Anton, Wendtner, Clemens-Martin, Eichhorst, Barbara and Hallek, Michael (2015). The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol., 11 (13). S. 1895 - 1904. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Gerwin, Henrik, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael J., Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens Martin, Reiser, Marcel, Stauch, Martina, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2020). Ibrutinib versus placebo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Leuk. Lymphoma, 61. S. 18 - 21. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Maurer, Christian, Pflug, Natali, Bahlo, Jasmin, Kluth, Sandra, Rhein, Christina, Cramer, Paula, Gross-Ophoff, Carolin, Langerbeins, Petra, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Fischer, Norbert, Tausch, Eugen, Stilgenbauer, Stephan, Boettcher, Sebastian, Doehner, Hartmut, Kneba, Michael, Dreyling, Martin, Binder, Mascha ORCID: 0000-0003-0663-3004, Hallek, Michael, Wendtner, Clemens-Martin, Bergmann, Manuela and Fischer, Kirsten (2016). Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur. J. Haematol., 97 (3). S. 253 - 261. HOBOKEN: WILEY. ISSN 1600-0609